Omeros (OMER) Gross Profit (2014 - 2026)

Omeros (OMER) reported Gross Profit of $9.3 million for Q1 2026, up 108.49% sequentially from -$109.6 million in Q4 2021.

Omeros (OMER) Gross Profit (2014 - 2026) Analysis & Trends

Omeros (OMER) has 9 years of Gross Profit data on file, last reported at $9.3 million in Q1 2026.

For the quarter ending Q1 2026, Gross Profit changed N/A year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at -$70.6 million (down 37.28% YoY), and the FY2021 full-year result was $80.1 million, up 9.87% from the prior year.
Gross Profit climbed to $9.3 million in Q1 2026, from -$109.6 million in the prior quarter.
In the past five years, Gross Profit ranged from a high of $9.3 million in Q1 2026 to a low of $9.3 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Omeros	707.67 Mn	707.67 Mn	9.31 Mn

Download Data